Humanigen (OTCPK:HGEN.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

HGEN.Q Stoklara Genel Bakış

A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. Daha fazla detay

HGEN.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Gelir, geçen yıl 59% oranında azaldı

Anlamlı bir piyasa değeri yok ( $119 )

Negatif hissedar öz sermayesi

+ 2 daha fazla risk

Humanigen, Inc. Rakipler

ObsEva

OTCPK:OBSE.F

US$11.7k

Mymetics

OTCPK:MYMX

US$151.0

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

RegeneRx Biopharmaceuticals

OTCPK:RGRX

US$2.1k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Humanigen
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.000001
52 Haftanın En Yüksek Seviyesi	US$0.21
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	-1.34
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-100.00%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Hissedar Getirileri

	HGEN.Q	US Biotechs	US Pazar
7D	-99.5%	2.4%	2.2%
1Y	-100.0%	16.2%	31.7%

Getiri vs. Endüstri: HGEN.Q geçen yıl % 16.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: HGEN.Q geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is HGEN.Q's price volatile compared to industry and market?
HGEN.Q volatility
HGEN.Q Average Weekly Movement	102,515.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: HGEN.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: HGEN.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 50618% dan 102515% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	6	Cameron Durrant	www.humanigen.com

Humanigen, Inc. Temel Bilgiler Özeti

Humanigen'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HGEN.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$119.00
Kazançlar(TTM)	-US$53.63m
Gelir(TTM)	US$1.70m

0.0x

P/S Oranı

0.0x

F/K Oranı

HGEN.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HGEN.Q gelir tablosu (TTM)
Gelir	US$1.70m
Gelir Maliyeti	US$38.73m
Brüt Kâr	-US$37.03m
Diğer Giderler	US$16.61m
Kazançlar	-US$53.63m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.45
Brüt Marj	-2,179.40%
Net Kâr Marjı	-3,156.80%
Borç/Özkaynak Oranı	0%

HGEN.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company is no longer active

HGEN.Q Stoklara Genel Bakış

Risk Analizi

Humanigen, Inc. Rakipler

OTCPK:OBSE.F

US$11.7k

OTCPK:MYMX

US$151.0

OTCPK:INFI.Q

US$90.0

OTCPK:RGRX

US$2.1k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Recent updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Humanigen, Inc. Announces Board Changes

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.75

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Humanigen Receives Non-Compliance Letter from Nasdaq

Bernstein Liebhard LLP Announces Class Action Lawsuit Against Humanigen, Inc

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Pomerantz LLP Announces the Filing of a Class Action Against Humanigen, Inc. and Certain of its Officers

Consensus revenue estimates increase by 34%

First half 2022 earnings released

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Price target decreased to US$8.70

Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen plunges 57% as trial for COVID-19 therapy fails

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Consensus revenue estimates increase by 19%

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Forecast to breakeven in 2023

Consensus revenue estimates increase by 12%

Forecast to breakeven in 2023

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved

Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

FDA Declines Humanigen’s Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients

Price target decreased to US$28.33

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Chairman & CEO recently sold US$1.7m worth of stock

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Humanigen Submits Application to FDA for Emergency Use Authorization for lenzilumab in Covid-19

Humanigen submits lenzilumab COVID-19 EUA application to FDA

Eversana Advances Commercialization Readiness as Humanigen Announces Publication of Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Newly Hospitalized Covid-19 Patients

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Price target increased to US$32.14

Humanigen, Inc., Annual General Meeting, Jun 17, 2021

Humanigen, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Earnings beat expectations

Chief Accounting & Administrative Officer, Corporate Secretary and Treasurer has left the company

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

New 90-day high: US$23.83

Humanigen, Inc. Announces Executive Changes

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing